View printer-friendly version

Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016

GAITHERSBURG, Md., July 21, 2016 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 4, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.

This conference call can be accessed live by telephone or through Emergent’s website:

Live Teleconference Information:
Dial in number: (855) 766-6521
International dial in: (262) 912-6157
Passcode: 29444249 Live Webcast Information:
Visit www.emergentbiosolutions.com
and select the “Investors” section

Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: http://edge.media-server.com/m/p/7wsyx2ie/lan/en.

A replay of the call can be accessed on Emergent’s website www.emergentbiosolutions.com under “Investors.”Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: http://edge.media-server.com/m/p/7wsyx2ie/lan/en.

About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:
Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
240-631-3394
SchmittT@ebsi.com

Emergent BioSolutions

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.